The dominance of autologous CAR T-cell therapy in the early years of cell-based immunotherapy came with significant logistical and economic hurdles, including high manufacturing costs, long turnaround times, and the risk of cytokine release syndrome (CRS). **Natural Killer (NK) cell therapeutics** are emerging as a potentially superior alternative, particularly due to their capability to be...
فارسی
English
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Arabic